ASE Technology: AI Summit Feedback Points to Rising Utilization and Sustained High Capex

Core Conclusion

ASE Technology’s Asia AI Summit update confirms a cyclical margin recovery is now underway, with ATM utilization rising toward full levels and gross margins tracking to the upper end of the structural 24–30% range by 2H26. The capex plan—US$8.5bn in 2026 and at least that in 2027—signals a multi-year commitment to advanced packaging and testing capacity buildout, heavily skewed toward equipment. For investors, this means ASE is positioning for durable AI-related demand but also locking in elevated depreciation risk if utilization slips. The read-through is a clearer path to near-term earnings upside, balanced by a longer-cycle investment burden that requires sustained high loading to generate acceptable returns.

Evidence Chain

Utilization and margin trajectory. ATM utilization was ~80% in 1Q26. Management guided to 80%+ in 2Q, with 85% defined as full utilization. Gross margins are improving sequentially, expected to reach the high end of the 24–30% structural range in 2H. This operating leverage is the clearest short-term driver: each point of utilization gain above ~80% flows through at high incremental margins, given the high fixed-cost base in packaging and testing. The indication that full utilization can be approached without overshooting suggests tight supply and pricing discipline.

Capex scale and composition. 2026 capex is budgeted at US$8.5bn, split into US$3bn for buildings/infrastructure and US$5.5bn for machinery and equipment. Within equipment, testing accounts for 40%, packaging 55%, the rest EMS. The emphasis on testing equipment (40% of equipment capex) is notable—it indicates capacity expansion for high-end test services (e.g., system-level test for AI chiplets), which typically command premium pricing and higher margins than commodity packaging. Management expects 2027 capex to at least match 2026 and “could be higher.” This signals confidence in the demand pipeline, particularly for advanced packaging, but also cements a structural step-up in fixed costs and depreciation.

Advanced packaging opportunities still early-stage. ASE has a mini line for co-packaged optics (CPO) and participates in the supply chain, but it is not yet a material revenue contributor. Co-Packaged Silicon (CoPoS) products are in qualification; mass production timing is unclear. These are the high-growth vectors that would justify elevated capex, yet their contribution remains undefined. The investment case hinges on the assumption that qualification will convert to volume—a reasonable but unconfirmed premise.

Key Risks

The most acute risk is a utilization reversal. ASE’s margin recovery depends on maintaining ~85% loading. Any softening in end-demand—especially from AI buildout pauses—would quickly reverse the operating leverage and push margins back toward the lower end of the structural range. With US$5.5bn in equipment capex annually, a 5-point utilization drop could erase a significant portion of gross margin gains.

The capex trajectory creates a high fixed-cost burden. Even if 2027 capex matches 2026, the cumulative equipment spending implies a sharp rise in annual depreciation starting 2027–28. If advanced packaging and testing demand fails to materialize at expected volumes, returns on this investment cycle will be subpar. The “could be higher” language on 2027 capex further raises the risk of overcapacity if order visibility proves optimistic.

CPO and CoPoS timelines are unproven revenue drivers. With no clear mass production start, these initiatives cannot be banked as near-term offsets to the growing asset base. Delays or competitive pressures in qualification would leave ASE with expensive capacity lacking a high-value demand pull. Finally, the heavy testing equipment allocation—while strategically positive—exposes the company to any slowdown in chiplet-based architectures that require extensive testing.

Bottom line: ASE’s utilization-led margin expansion is investable in the near term, but the sheer scale of committed capex makes this a high-operational-gearing story. Sustained demand is required to justify the build, and the advanced-packaging pipeline is not yet de-risked. Investors should weigh the 2H26 margin upside against the structural depreciation headwind that will persist into 2028 and beyond.